Products
Host Cell Residue Detection
Process Impurity Assay
Advnetitious Agent/Microorganism Testing
Pyrogen / Endotoxin Detection
Genetic Stability
Cell Line Characterization
Viral Titer Assay
Detection Equipment
Biochemical Reagents
Special Host HCD Detection-Custom Residual DNA Detection for Rare & Non-Standard Production Hosts
30+ Special Hosts | FDA/EMA/NMPA | Full Validation |5‑7 Weeks Total Cycle
In biopharmaceutical manufacturing, beyond common hosts like E. coli and yeast, special engineered strains (actinomycetes, filamentous fungi, rare prokaryotic/eukaryotic cells) are widely used for complex molecules.
Regulatory authorities require strict residual host cell DNA (HCD) monitoring for drugs produced with non-standard hosts. Due to unique genomes, commercial kits are unavailable, requiring fully customized method development.
Regulatory Mandate
Pharmacopoeias require validated HCD assays for non‑standard host‑derived drugs to ensure patient safety.
Common Special Hosts
Actinomycetes (Streptomyces, Amycolatopsis)
Filamentous fungi (Aspergillus, Penicillium)
Rare prokaryotes (Arthrobacter, Paenibacillus)
Special eukaryotic cells
| Advantage | What It Means for You |
| Complete Development System | Full workflow: genome extraction, target screening, primer/probe design, optimization & validation. |
| Regulatory Compliance | Fully compliant with USP/EP/ChP guidelines for specificity, sensitivity, accuracy & robustness. |
| Customized Design | Tailored targets & reaction systems based on host genome & manufacturing process. |
| Extensive Experience | Proven track record with 30+ special hosts, supporting global drug registrations. |
The following representative projects have successfully supported client submissions to FDA and EMA:
| No. | Product Name | Host Organism |
| 1 | Clobetasol Propionate | Arthrobacter simplex |
| 2 | Daptomycin | Streptomyces roseosporus |
| 3 | Lincomycin HCl | Streptomyces lincolnensis |
| 4 | Vancomycin HCl | Amycolatopsis orientalis |
| 5 | Lovastatin | Aspergillus terreus |
| 6 | Coenzyme Q10 | Rhodobacter sphaeroides |
| 7 | Lactase | Aspergillus oryzae |
*The above represents a partial case portfolio
Total project cycle: 5-7 weeks, subject to project complexity
1. Solution Design（0.5‑1 Week）
Demand communication
Host information confirmation
Scheme output
Contract signing
2. Host DNA Extraction & QC（1 Week）
Host genomic DNA extraction
DNA quality inspection (quantity & purity)
3. Detection System Screening（1 Week）
Primer‑probe screening
Bioinformatics & NGS (optional)
System confirmation (recovery & LOQ)
4. Method Validation（2-3 Weeks）
Linearity & range
LOD, LOQ, specificity
Accuracy & precision
Robustness
5. Project Delivery（0.5-1 Week）
Sample testing
Method validation report
Method transfer support
Custom kit development
Q1: Why can’t commercial kits be used for special hosts?
A:Commercial kits target common hosts (E. coli, CHO). Special hosts have unique genomes with no cross‑reactivity, requiring custom primer/probe design.
Q2: What is the typical timeline for method development?
A: Total 5‑7 weeks: Design 0.5‑1w → DNA extraction 1w → System screening 1w → Validation 2‑3w → Delivery 0.5‑1w.
Q3: What regulatory standards do you comply with?
A: USP <1131>, EP 2.6.34, ChP 3407, ICH Q2. Suitable for FDA/EMA/NMPA submissions.
Q4: What sensitivity can you achieve?
A:LOD ≤30 fg/reaction, LOQ ≤300 fg/reaction, meeting global regulatory limits.
Partner with our experts for custom HCD method development & regulatory support within 5‑7 weeks.
返回
